Skip to main content
Top
Published in: Endocrine Pathology 4/2008

01-12-2008 | REVIEW

Challenging Lesions in the Differential Diagnosis of Endocrine Tumors: Parathryoid Carcinoma

Author: Ronald A. DeLellis

Published in: Endocrine Pathology | Issue 4/2008

Login to get access

Abstract

Parathyroid neoplasms encompass a spectrum of proliferative lesions that include adenomas, atypical adenomas, and carcinomas. While the diagnosis of adenomas is usually straightforward, parathyroid carcinomas (PTCAs) often present considerable diagnostic challenges. Fibrosis and mitotic activity are common in PTCAs, but these features are not specific for malignancy. An unequivocal diagnosis of PTCA should be restricted to those tumors that invade adjacent soft tissues, thyroid gland, blood vessels, or perineural spaces or to those cases with documented metastases. Atypical adenomas include those tumors that share some of the features of PTCA but lack evidence of invasive growth. A variety of genetic abnormalities, including HRPT2 mutations, occur in PTCAs. Mutations of the HRPT2 gene, which encodes parafibromin, are responsible for the development of the hyperparathyroidism–jaw tumor syndrome and have also been implicated in the development of a high proportion of sporadic PTCAs. Correlative immunohistochemical studies have revealed nuclear parafibromin immunoreactivity in adenomas but absence or partial loss of staining in PTCAs. While parafibromin immunohistochemistry represents an important step in the ability to diagnose PTCA, additional studies will be required to test the validity of this approach and to determine the roles of other genes in the development of these tumors.
Literature
1.
go back to reference DeLellis RA, Mazzalia P, Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 132:1251–62, 2008.PubMed DeLellis RA, Mazzalia P, Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 132:1251–62, 2008.PubMed
2.
go back to reference Bondeson L, Grimeluis L, DeLellis RA, et al. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PN, Eng C, eds. Pathology and genetics of tumours of endocrine organs (WHO classification). Lyon: IARC, pp. 224–7, 2004. Bondeson L, Grimeluis L, DeLellis RA, et al. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PN, Eng C, eds. Pathology and genetics of tumours of endocrine organs (WHO classification). Lyon: IARC, pp. 224–7, 2004.
4.
go back to reference Norris EH. Collective review. Carcinoma of the parathyroid glands with a preliminary report of 3 cases. Int Abstracts of Surg 86:1–21, 1948. Norris EH. Collective review. Carcinoma of the parathyroid glands with a preliminary report of 3 cases. Int Abstracts of Surg 86:1–21, 1948.
5.
go back to reference Castleman B. Tumors of the Parathyroid Glands. Atlas of Tumor Pathology. Section IV—Fascicle 15. Armed Forces Institute of Pathology. Washington, DC 1952. Castleman B. Tumors of the Parathyroid Glands. Atlas of Tumor Pathology. Section IV—Fascicle 15. Armed Forces Institute of Pathology. Washington, DC 1952.
7.
go back to reference Snover D, Foucar K. Mitotic activity in benign thyroid diseases. Am J Clin Pathol 75:345–7, 1981.PubMed Snover D, Foucar K. Mitotic activity in benign thyroid diseases. Am J Clin Pathol 75:345–7, 1981.PubMed
8.
go back to reference DeLellis RA. Tumors of the parathyroid glands. Atlas of tumor pathology, 3rd series, fascicle 6. Washington DC: Armed Forces Institute of Pathology, 1993. DeLellis RA. Tumors of the parathyroid glands. Atlas of tumor pathology, 3rd series, fascicle 6. Washington DC: Armed Forces Institute of Pathology, 1993.
10.
go back to reference Levin KE, Chew KL, Ljung BM. Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas. J Clin Endocrinol Metab 67:770–4, 1988.CrossRef Levin KE, Chew KL, Ljung BM. Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas. J Clin Endocrinol Metab 67:770–4, 1988.CrossRef
12.
go back to reference Guiter GE, DeLellis RA. Risk of recurrence or metastasis in atypical parathyroid adenoma. Mod Pathol 15:115A, 2002, (Abstract).CrossRef Guiter GE, DeLellis RA. Risk of recurrence or metastasis in atypical parathyroid adenoma. Mod Pathol 15:115A, 2002, (Abstract).CrossRef
16.
go back to reference Kytola S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 157:570–6, 2000. Kytola S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 157:570–6, 2000.
17.
go back to reference Erickson LA, Jalal SM, Harwood A, Sherer B, Jin L, Lloyd RV. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol 38:578–4, 2004. doi:10.1097/00000478-200405000-00003. Erickson LA, Jalal SM, Harwood A, Sherer B, Jin L, Lloyd RV. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol 38:578–4, 2004. doi:10.​1097/​00000478-200405000-00003.
18.
go back to reference Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosome 1p and 11q in parathyroid carcinoma. J Pathol 202:86–4, 2004. doi:10.1002/path.1489.PubMedCrossRef Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosome 1p and 11q in parathyroid carcinoma. J Pathol 202:86–4, 2004. doi:10.​1002/​path.​1489.PubMedCrossRef
19.
go back to reference Valimaki S, Forsberg L, Farnebo LO, Larsson C. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol 21:727–5, 2002.PubMed Valimaki S, Forsberg L, Farnebo LO, Larsson C. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol 21:727–5, 2002.PubMed
21.
go back to reference Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility BRCA2 loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endocrinol (Oxf) 45:195–200, 1996. doi:10.1046/j.1365-2265.1996.d01-1561.x.CrossRef Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility BRCA2 loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endocrinol (Oxf) 45:195–200, 1996. doi:10.​1046/​j.​1365-2265.​1996.​d01-1561.​x.CrossRef
24.
25.
go back to reference Teh BT, Sweet KM, Morrison CD. Hyperparathyroidism–jaw tumor syndromeIn: DeLellis RA, Lloyd RV, Heitz PN, Eng C, eds. Pathology and genetics of tumours of endocrine organs (WHO classification).. Lyon: IARC, pp. 228–9, 2004. Teh BT, Sweet KM, Morrison CD. Hyperparathyroidism–jaw tumor syndromeIn: DeLellis RA, Lloyd RV, Heitz PN, Eng C, eds. Pathology and genetics of tumours of endocrine organs (WHO classification).. Lyon: IARC, pp. 228–9, 2004.
30.
go back to reference Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism–jaw tumor associated adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140–49, 2006. doi:10.1097/01.pas.0000209827.39477.4f.PubMed Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism–jaw tumor associated adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140–49, 2006. doi:10.​1097/​01.​pas.​0000209827.​39477.​4f.PubMed
31.
go back to reference Cetani F, Ambrogini E, Viacava P, et al. Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma. Europ J Endocrinol 156:547–4, 2007. doi:10.1530/EJE-06-0720.CrossRef Cetani F, Ambrogini E, Viacava P, et al. Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma. Europ J Endocrinol 156:547–4, 2007. doi:10.​1530/​EJE-06-0720.CrossRef
32.
go back to reference Juhlin CC, Villablanca A, Sandelin K, et al. Parafibromin immunoreactivity; its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14:501–2, 2007. doi:10.1677/ERC-07-0021.PubMedCrossRef Juhlin CC, Villablanca A, Sandelin K, et al. Parafibromin immunoreactivity; its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14:501–2, 2007. doi:10.​1677/​ERC-07-0021.PubMedCrossRef
33.
go back to reference Tominaga Y, Tsuzuki T, Matsuoka A, et al. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 32:815–1, 2008. doi:10.1007/s00268-007-9458-8.PubMedCrossRef Tominaga Y, Tsuzuki T, Matsuoka A, et al. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 32:815–1, 2008. doi:10.​1007/​s00268-007-9458-8.PubMedCrossRef
34.
go back to reference Mangray S, Kurek KC, Sabo E, DeLellis RA. Immunohistochemical expression of parafibromin is of limited value in distinguishing parathyroid carcinoma from adenoma. Mod Pathol 21:108A, 2008, (abstract). Mangray S, Kurek KC, Sabo E, DeLellis RA. Immunohistochemical expression of parafibromin is of limited value in distinguishing parathyroid carcinoma from adenoma. Mod Pathol 21:108A, 2008, (abstract).
Metadata
Title
Challenging Lesions in the Differential Diagnosis of Endocrine Tumors: Parathryoid Carcinoma
Author
Ronald A. DeLellis
Publication date
01-12-2008
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 4/2008
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9050-2

Other articles of this Issue 4/2008

Endocrine Pathology 4/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.